Table 1 Baseline characteristics of patients

Demographics

Age (years), mean ± SD

59.90 ± 9.22

60.28 ± 9.52

Gender

 Female

93 (49%)

71 (39%)

 Male

97 (51%)

109 (61%)

BMI^a

23.4 (21.47–25.9)

23.44 (22.03–25.13)

Smoke

59 (31%)

60 (33%)

Drink alcohol

45 (24%)

60 (33%)

Abdominal discomfort

88 (46%)

99 (55%)

Weight loss(> 5 kg)

39 (21%)

57 (30%)

PET/CT parameters

Tumor size (mm)^a

 Max

31.5 (26.0–45.0)

31 (27.0–42.0)

 Min

26 (20.0–35.5)

25 (19.5–33.0)

Tumor SUVmax^a

5.75 (4.4–7.95)

7.5 (5.6–9.6)

Liver SUVmean

2.30 (2.02–2.54)

2.30 (2.02–2.54)

SUVR

2.74 (1.60–3.01)

3.48 (2.27–4.11)

Location

 Head–neck

103 (54%)

121 (67%)

 Body–tail

87 (46%)

59 (33%)

Pathological report

Neuroaggression

113 (59%)

109 (61%)

Cancer embolus

15 (8%)

38 (21%)

Lymph node metastasis

58 (31%)

58 (32%)

Laboratory findings^a

ALT(U/L)

22.2 (11.5–58.7)

17.2 (13.2–98.5)

AST(U/L)

17.70 (13.5–49.3)

18.75 (13.5–50.8)

Total bilirubin(umol/L)

12.4 (8.7–18.6)

15.7 (8.7–32.7)

Direct bilirubin(umol/L)

4.4 (2.9–8.8)

4.9 (2.7–20.5)

Glucose (mmol/L)

5.97 (5.2–7.0)

5.48 (4.8–6.9)

CEA (μg/L)

2.77 (1.8–5.0)

3.02 (2.0–4.7)

CA125(U/mL)

14.46 (8.7–25.4)

18.96 (11.7–34.7)

CA199(U/mL)

170.25 (47.8–611.2)

229 (70.5–738.4)